Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the
Gilead got permission to sell a new cancer medicine combo in Europe. This shows the company's medicine works, which is good news about its business and might interest people who own or watch the stock.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.